H. pylori infections occur across the world due to exposure to saliva or stool in contaminated water or food. Learn how the ...

Study finds underutilization of fidaxomicin, a recommended treatment for C. diff infection, despite increased use in hospitals.

The global health organization says the lack of rapid diagnostic tests results in undertreatment and overtreatment of ...

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...

In the period spanning 2017-2021, a mere 12 new antibiotics entered the market, with only one capable of targeting all the ...

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.

Joyce Beatty (D-OH) on cancer research and treatment Javascript must be enabled in order to access C-SPAN videos. *This text was compiled from uncorrected Closed Captioning.

The stigma linking HIV to the LGBTQ+ community led to poor funding for treatment and unfair treatment ... along with viral infections such as hepatitis C and COVID-19. They block protease, an ...

Detailed price information for Citigroup Inc (C-N) from The Globe and Mail including charting and trades.

diff., a bacterium that can cause serious infections in the colon. Symptoms can range from mild diarrhea and stomach pain to significant colon damage, which can sometimes require surgery. “Antibiotics ...

There are about 500,000 cases of C. difficile each year; about one in six people with the infection will see it come back within two to eight weeks of the initial infection. “Treatment of C.